# Phase II Trial of S101 Autologous Anti-CD7 CAR-T Cells in Patients With R/R T-LBL/ALL.

> **NCT07244380** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Hebei Senlang Biotechnology Inc., Ltd.** · enrollment: 38 (estimated)

## Conditions studied

- T Lymphoblastic Leukemia/Lymphoma

## Interventions

- **BIOLOGICAL:** Autologous CD7-targeting CAR T cells

## Key facts

- **NCT ID:** NCT07244380
- **Lead sponsor:** Hebei Senlang Biotechnology Inc., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-11-28
- **Primary completion:** 2026-09-30
- **Final completion:** 2028-06-30
- **Target enrollment:** 38 (ESTIMATED)
- **Last updated:** 2025-11-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07244380

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07244380, "Phase II Trial of S101 Autologous Anti-CD7 CAR-T Cells in Patients With R/R T-LBL/ALL.". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT07244380. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*